OCTO Acquires Nebula Systems, Reinforces Its Leadership in Intelligent Vehicle Diagnostics
4.12.2019 14:00:00 EET | Business Wire | Press release
OCTO Telematics, the leading global provider in transforming an IoT Big Data set into actionable intelligence, has acquired the entire share capital of Nebula Systems Ltd.
Nebula specialises in the development of advanced cloud technologies for the automotive and connected car industries. This means that its proprietary technologies are now available to make vehicle systems and data more accessible, so that a vehicle’s health, status and operation can be monitored, analysed, diagnosed and maintained, faster and more effectively than ever before - anytime and anywhere.
OCTO continues its investment strategy in companies with high technological value, pursuing continuous portfolio innovation and market leadership. The acquisition confirms OCTO’s unwavering commitment to respond to the increasing demand for vehicle usage data analysis tools, with advantages for insurance, automotive and mobility companies with its increasingly integrated and complete offering.
Modern cars are full of sensors that generate huge amounts of valuable data that can be used to enhance both the driver and fleet manager experience. The vast majority of this data is related to OEM Electronic Control Unit (ECU), protocol and CAN bus which are difficult for the aftermarket to access. The Nebula Systems diagnostic cloud solution is based on an integrated circuit and a suite of vehicle data analysis software applications in order to better respond to the increased complexity. An integrated circuit, developed with proprietary technology, grants deep access to OEM level data. Vehicle telematics can therefore benefit from combining this telematics chipset with proprietary analysis software, which gives OCTO the ultimate flexibility and ease of access to OEM vehicle data by using a unique VIN-specific configuration file that contains the instructions to read Parameter ID (PID) sets from any OEM ECU on virtually any car.
This technology uniquely combines the proprietary chipset and a cloud-based VIN interpreter and configuration files builder to fully access all the ECUs and thousands of PIDs a vehicle may have.
“We are very proud of this latest acquisition which places OCTO amongst the leading providers of fleet telematics leasing and renting organizations” says Nicola Veratelli, OCTO Group CEO. “Amongst many trends that are changing the mobility sector there are some that have a significant impact on fleet managers, such as the need to integrate data coming from the vehicle, each different from the other and defined for each manufacturer. OCTO solves the complexity of interpreting this data and offers impactful solutions which contribute to deliver additional value for fleet managers. We are committed to offer dozens of fleet telematics services to fleet managers and drivers: remote cloud-based diagnostics deriving from this Nebula acquisition is surely one of the most relevant.”
With this acquisition, the Nebula technology will be integrated in the standard OCTO offering. Furthermore, all OCTO telematics devices will integrate these capabilities, allowing OCTO solutions full access to all OEM ECUs and to use diagnostic trouble codes and Parameter IDs for the benefit of both drivers and fleet managers. The combination of these benefits will have a substantial impact on mobility management costs for fleet managers using the OCTO Fleet Telematics solution.
About OCTO
Founded in 2002, OCTO is today the Number 1 global provider of telematics and data analytics solutions for the auto insurance industry and, increasingly, a major player in Fleet management services, with world-class solutions to grow its core businesses – Insurtech and Intelligent Mobility – and to expand and provide innovative connected solutions in new industries and international markets.
OCTO’s vision is to connect the world of mobility through advanced analytics and IoT-driven services for a new era of Smart Telematics.
OCTO currently has 6 million connected users, holds the largest global database of telematics data, with more than 248 billion miles of driving data collected and over 464,000 crashes and insurance events analysed, and runs more than 10 car sharing services with more than 400,000 hires per month.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005088/en/
Contact information
OCTO Telematics
Adriana Zambon
press.it@octotelematics.com
m: +39 339.3995640
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom